Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Aphria Inc (NYSE:APHA)
Q1 2020 Earnings Call
Oct 15, 2019, 9:00 a.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Operator

Good morning. My name is Denise, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Aphria Inc Q1 Quarterly Investors Call. [Operator Instructions] Thank you.

Katie Turner you may begin your conference.

Katie M. Turner -- Investor Relations

Thank you, Denise. Good morning, everyone. We appreciate you joining us to discuss Aphria Inc's financial results for the first quarter ended August 31st, 2019.

On today's call are Irwin Simon and Carl Merton, Jim Meiers will also be available for Q&A. By now, everyone should have access to the earnings release, financial statements, MD&A and investor presentation, which are available on the Investors section of Aphria's website, at aphriainc.com. The financial statements have been filed with SEDAR and EDGAR.

Before we begin, please remember that during the course of this call management may make forward-looking statements. These statements are based on management's current expectations and beliefs and involve various known and unknown risks and uncertainties, which may prove to be incorrect, and actual results could differ materially from those described in these forward-looking statements. Please refer to the text in Aphria's earnings press release and financial filings issued today for a discussion of the risks and uncertainties associated with such forward-looking statements.

And now I'd now like to turn the call over to Irwin Simon.

Irwin D. Simon -- Interim Chief Executive Officer

Thank you, Katie, and good morning, everyone. We appreciate you joining us today to discuss our first quarter financial results. Our team has accomplished a significant amount to start the year both in Canada and internationally. For the first quarter, our results were in line with our expectations and we're on track to achieve our annual guidance. We believe our financial results truly sets us apart from our peers in the cannabis industry.

Adult-Use cannabis net revenue increased 8% with a four-fold increase in consolidated adjusted EBITDA as compared to the fourth quarter. We ended the quarter with a strong balance sheet and a cash position including CAD464 million of cash and marketable securities. As they say, cash is king. Our cash position and balance sheet will continue to differentiate us in the cannabis industry.

We remain focus on the highest return priorities for growth. Our first quarter results demonstrate our emphasis on sustainable profitable growth. Since I joined Aphria, our focus has been on profitability, a strong cash position for growth and focusing on our assets that we believe will create the most value as we invest in them to grow, demonstrate by our performance and these strategies are working.

We have assembled a strong team with cannabis, consumer packaged goods, beverage and broader operational and supply chains experience, that will fuel our growth this year and years to come well into the future. Most recently, Bernard Yeung joined us as Vice President Sales. He is a dynamic executive with significant experience in the cannabis and the alcohol industry. He is already hit the ground running at Aphria with compelling insights and perspectives that help further our growth as we consistently enhance our competitive position in both the adult-use and the medical cannabis industry.

In addition, Denise Faltischek has joined our team bringing a tremendous depth of consumer packaged goods experience, particularly in the natural organic industry. Over her career, she has led teams to complete over 50 acquisitions, while accelerating top line growth, profitability and generating value for her shareholders. She will work with me on our global strategic alliance, including future strategic partnerships in both the US and international. She will also oversee our quality control and our assurance teams, as well as the medical and international businesses. We're excited to have these two talented executives on board and look forward to their future contributions.

Our more than 1,200 team members worldwide are delivering on their key initiatives to fulfill our mission to be a premier global cannabis company with our medical and adult-use cannabis brands. We continue to build upon our existing business fundamentals and capabilities, streamlined processes through technology with our new ERP systems and greater automation in our facilities, all with an emphasis on consistent execution and to drive profitability and quality.

At Aphria, we strive to be better in all that we do. So we can further our industry-leading position. We have compelling brands for patients and consumers across broad demographics, and our team is always working to further brand development. We believe, we can increasingly connect with consumers through our brands positioning them to drive growth through innovation and return value to our shareholders.

As the cannabis industry continuously evolves globally, at Aphria, we're also evolving that rapid pace to ensure we stay ahead by leveraging our core capabilities. In Leamington, we enhanced our operations team to generate improved quality and higher yields at a lower cost. We have a great video -- video available on our website to illustrate the increased automation at our state-of-the-art facilities. At Aphria One, we are fully licensed and planted with nearly 600,000 plants. Our 100 acre Aphria Diamond premier greenhouse featured 1.3 million square feet of production. The facility is fully constructed and ready to be operational.

We have been working proactively with Health Canada to secure licensing for the facility. The team at Health Canada has gone above and beyond to work through Aphria Diamond's license process particularly, since the end of June. On Friday, we were advised by Health Canada, that they are in the process of expediting the issuance of the license. We're excited about the tremendous growth opportunities we will have as a result of expanding our total annual domestic production capabilities in Canada to 255,000 kilograms.

We look forward to addressing industrywide supply constraints with our expanded production capabilities. In addition, we remain confident, we will obtain our EU GMP certification for bulk and finished product in the first half of this fiscal year, enabling us to export product to meet the growing demands of the European and South American markets. Today, Aphria has five high-quality brands, including Solei, RIFF, Good Supply, Broken Coast and our Aphria Medical brand. Aphria's success will continue to be driven by our differentiation portfolio of brands and products aimed at delightful distinct consumer segments. In fact, our adult-use brands continue to receive industrywide recognition.

Aphria brands continue to gain momentum in the Canadian marketplace. According to OCS data, we've reached a 12% market share, that is excellent. We were able to gain a significant amount of share during the quarter from our competitors driven by brand awareness, nationwide distribution and the quality of our products. Now that Bernie has started just think what else we're going to achieve.

Broken Coast, our industry-leading premium craft products continues to be among the only brand consumers consistently ask for by name and the industry. We believe over time our Broken Coast brand has the potential to be the number one premium brand in Canada. Solei continues to appeal to new consumers. It ranks number three in the non-flower category. And Solei's CBD oil, Solei Free is consistently ranked as a top seller according to the OCS.

Good Supply entered the market later, and despite a smaller SKU count has already shown great momentum for the enthusiastic heavy user looking for a great product at great, great value. We expect momentum to continue with these brands. We believe the quality of our brands remained unmatched in the industry. We put patient and consumer needs at the forefront of our strategy. As regulations change, we will be proactive on our portfolio of brands and products.

To this point, our entry into new product markets will be done in a strategic and thoughtful manner, where the best opportunities exist for differentiation. This includes vapes, as I previously mentioned as well as edibles, peas, beverage and topicals. We believe the expected legalization of vapes and concentrates will create a significant opportunity in the Canadian market, providing more choice and new experiences, while opening the door to a range of new consumers and new products.

In Canada, we're excited to bring our premium cannabis extracts to disposables, [Indecipherable] and the PAX Era device and platform. I want to address some of their concerns surrounding vapes. The news coming from the US is something we're continuously monitoring. Our number one priority is always to protect the health and safety of our patients and consumers by ensuring we only sell high quality cannabis products, is our understanding that these illnesses are linked to products coming off the illicit markets, specifically cutting agents and other additives in the oils as well as faulty hardware versus the cannabis itself. This is why, a continuous education and having a regulated market is so important.

Patients and consumers need to be confident the products and the brands they are consuming comply with quality and safety regulations and we will ensure that is happening. In addition, to our quality assurance and our management process, we've taken appropriate -- appropriate precautions, including only working with reputable suppliers, launch of platform mandates to provide education to Canadians above all forms of cannabis that are available now and in the future.

Health Canada has shown great leadership in establishing a regulated market that puts safety first. And we'll continue to work closely with regulators as regulations evolve. We will continue to collaborate with a growing roster of strategic innovation partners such as PAX, Manna Molecular Science, Rapid Dose Therapeutics. As we pursue new technologies and delivery systems that will change the way patients and consumers interact with cannabis in the future.

Internationally, we're very pleased with the process we have made since being granted the maximum number of lots within the German tender process. Aphria is the only licensed producer in Germany with permission to grow all three strains of medical cannabis approved by the German authority. In Colombia, we are in the final contract stages for greenhouse facility that will have GMP cultivation and processing capabilities. This will soon enable us to play a leading role in the local market as well as a developed low cost export opportunities across the Latin America region.

We are also committed to supporting and enabling the medical community through our exclusive partnership with Colombia Medical Federation, a highly respected organization with direct access to over 70,000 doctors and medical professionals. We plan to host our first event with speakers from the medical cannabis industry worldwide in November. With more than 650 million people in LATAM, we believe there is an incredible opportunity.

In Buenos Aires, we're working on the Hospital Garrahan in the region to collaborate on a clinical study focused on children with epilepsy. We are honored to work with them as we learn more together about how CBD-based products to become a large part of patients healthcare regime. In the US, we're focused on building strategic partnership and alliances for growth with the emphasis on the CBD market until medical cannabis is fully legalized. We believe Aphria can generate strong growth in the US over time. If we look to the future, we continue to believe Aphria will be a consumer packaged goods company and with that comes plenty of options for us in the US market, which we know greatly.

Last but certainly not least, as we continue to deliver on our commitment to give back to both people and the planet, we launched Planet Positivity [Phonetic], a new component of our corporate social responsibility strategy. Plant Positivity champions, the incredible power, the plants have an overall well-being and provide great access to green spaces for communities. Aphria is increasingly well-positioned with the right team, global infrastructure, strategic initiatives, production capabilities and capital to support our growth in fiscal 2020, and well into the future. We have great momentum in Latin America, including Colombia, Argentina, Paraguay and Jamaica, as well as Germany. And across our international markets, as we continue to strengthen our global footprint.

Together, the team at Aphria has entrepreneurial culture that is grounded into accountability. We're all working together toward our corporate objective of generating CAD1 billion run rate by the end of calendar year 2020. And with that margins will continue to improve to fuel profitability and cash flow. We believe the opportunities for long-term shareholder value creation are very strong, both in Canada, US and internationally.

I would like to thank our Board of Directors, as some of them will not be seeking reelection at our next AGM. I also like to thank my leadership team and my direct reports for all their help getting us to where we are today and their continued dedication to moving this company forward.

With that, I would now like to turn the call over to Carl.

Carl Merton -- Chief Financial Officer

Thank you, Irwin, and good morning. Please note all financial references are in Canadian dollars unless I mention otherwise. As Irwin discussed, in the first quarter, we continue to execute on our growth initiatives and prioritize profitability as we continue to position our business for long-term growth and success. We are pleased with our financial results, particularly our cannabis revenue growth, sequential positive adjusted EBITDA, and our ability to maintain a strong balance sheet and cash position.

As a result, we remain on track to achieve our fiscal 2020 guidance. This speaks to the strength of our team and the strategic initiatives we are working together to execute every day at Aphria. Focusing on our capacity, our Aphria One facility is fully licensed and planted, and as Irwin mentioned, we have been advised that Health Canada is in the process of expediting the issuance of Aphria Diamond's license, keeping us on track to achieve our annual production capacity.

Moving to our financial results. We are pleased with our first quarter results, particularly our continued increase in cannabis sales and our profitability improvement. Net revenue in Q1 increased 849% over the prior year period to CAD126.1 million. Compared to Q4, cannabis revenue increased 30.8 -- sorry, increased to CAD30.8 [Phonetic] million from CAD28.6 million.

Distribution revenue was above our expectations for the quarter, but showed a slight decrease from CAD99.2 million to CAD95.3 million in the quarter. The slightly lower distribution revenue for Q1 from Q4 is associated with a conscious change we made in CC Pharma's business strategy to maximize profitability after recent changes in the German Government's medical reimbursement model. As a result, we are pleased to report CC Pharma has successfully navigated the change in that reimbursement model, increasing its gross margins and EBITDA, in spite of the governmental changes. The entire CC Pharma team is working to further implement the change in strategy, as well as preparing the business for the importation of EU-GMP certified cannabis from Canada. Facility, additions are well on their way and they already have pharmacies reaching out for pre-orders.

We look forward to supplying Germany's first domestically growing medical cannabis in late calendar 2020 from our new cultivation facility in Neumunster. The entire Aphria team in Germany is focused on positioning in Aphria with the most comprehensive license in the country as a dominating force in the German cannabis market. In Canada, we experienced a small fire at our Broken Coast facility in British Columbia that impacted cannabis revenue during the quarter by approximately CAD1.5 million that will be made up in the balance of the year. Our team, led by Graeme Holfeld did a tremendous job to act swiftly and quickly resume the full operations in just a few short weeks. The amount of effort that went into reopening the facility was phenomenal. We continue to believe we have tremendous runway for growth with our Broken Coast brand of cannabis products.

The company sold 5,969 kilogram equivalents of cannabis in Q1, up 7% compared to 5,574 kilogram equivalents. Adult-use cannabis accounted for 3,317 kilogram equivalents and medical cannabis accounted for 1,354 kilogram equivalents. Adult-use net revenue increased 8% from the fourth quarter of 2019 to CAD20 million, despite the fire at Broken Coast. The average selling price of adult use cannabis inclusive of excise tax increased to CAD6.02 per gram in Q1, compared to CAD5.73 per gram due to a more profitable product mix. The average selling price of medical cannabis inclusive of excise tax decreased to CAD7.56 per gram in Q1 compared to CAD7.66, primarily related to a higher percentage of total medical sales coming from Aphria.

During the quarter, our cash cost program increased from CAD1.35 last quarter to CAD1.43, as we continue to ramp production in our facility. Included in this figure is CAD0.20 a gram related to the strategic decision to allocate flowering space to mothers to facilitate the ramp up of our Aphria Diamond expansion. We expect this temporary increase to continue until the Aphria Diamond expansion is fully planted. Our all-in cost per gram increased from 235 a gram to 252 a gram largely for the same reasons.

Adjusted cannabis gross profit increased slightly to CAD15.3 million from CAD15.2 million. Adjusted cannabis gross margin was 49.8% in Q1, compared to 53%. The decrease was primarily due to lower sales of higher margin items due to the Broken Coast fire and temporary higher cost per gram. Adjusted distribution gross profit decreased slightly to CAD12.2 million from CAD12.3 million in Q4. Adjusted distribution gross margin increased to 12.8%, compared to 12.4% in Q4.

SG&A costs in Q1 decreased approximately CAD20 million compared to the prior period. The decrease in SG&A was primarily due to the prior quarter, including CAD19.5 million in transaction costs, primarily associated with the issuance of the senior convertible debenture, a decrease of CAD3.9 million of general and administrative costs, all partially offset by an increase in share-based compensation and amortization.

Our first quarter was profitable for the second consecutive quarter with net income of CAD16.4 million, or CAD0.07 per share, compared to net income of CAD15.8 million, or CAD0.05 per share in Q4, and a net loss of CAD0.09 per share in Q1 last year. The consolidated adjusted EBITDA in the first quarter increased by CAD0.8 million to CAD1 million, based on adjusted EBITDA from cannabis operations of CAD1.3 million, adjusted EBITDA from distribution operations of CAD3.9 million, both partially offset by an adjusted EBITDA loss from businesses under development of CAD4.2 million. The increase in adjusted EBITDA is primarily attributable to cost containment strategies employed at our businesses under development and was our second consecutive quarter of positive adjusted EBITDA. Our team remains intently focused on future profit growth.

Moving to liquidity. We continue to have a solid cash position and strong balance sheet. As of August 31st, 2019, the company had near cash of CAD464 million available for use and over CAD500 million of proforma cash, when including the receivable related to our settlement with GGB [Phonetic]. This amount is more than sufficient to fund previously announced capex, working capital and strategic investments.

In the first quarter, the company used approximately CAD100 million of cash in the business. This amount was unusual and is not representative of future quarters. Cash outflows in the quarter included approximately CAD35 million for the final earn-out related to our CC Pharma acquisition, an important part of our German strategy. CAD5 million of one-time payments on our long-term debt, CAD30 million of capex, and a CAD15 million increase in working capital supporting our increased production capacity. We anticipate a much lower capex in the second quarter, somewhere between CAD20 million and CAD25 million, depending upon the timing of delivery of the equipment purchases. Further, we expect lower working capital requirements beginning in Q2. Going forward, we expect to generate solid cash flow. We believe this future cash flow when combined with our existing cash position and strong balance sheet will support our growth initiatives in both Canada and internationally.

Turning to our outlook. For fiscal 2020, we continue to expect to report net revenue of approximately CAD650 million to CAD700 million with distribution revenue representing slightly more than half of the total net revenue. In addition, we expect to report adjusted EBITDA of approximately CAD88 million to CAD95 million. Applying our average selling price to our future production capacity, we continue to expect annualized revenue of CAD500 million in Canadian cannabis sales once all facilities are in full crop rotation. And two , annualized revenue of CAD1 billion in Canadian cannabis sales by the end of Calendar Year 2020, both of which strengthen our position as a leading global cannabis company.

In summary, at Aphria, we have the greenhouse space, cultivation expertise, extraction capacity, automation technology, differentiated brands, product innovation and raw materials position us for success. And as we gain scale, we will gain efficiencies in Canada. Those efficiencies will allow us to build out international distribution for our medical and adult-use cannabis. We are pleased with our financial results this quarter and we continue to execute on our strategic priorities to be a stronger, more profitable company. Aphria has a long runway of growth ahead. We are confident in our ability to create long-term shareholder value. That concludes our formal remarks.

Irwin, I -- Irwin and I are now available for your questions. Operator, back to you.

Questions and Answers:

Operator

Thank you. [Operator Instructions] And your first question comes from the line of Owen Bennett with Jefferies. Your line is open.

Owen Bennett -- Jefferies -- Analyst

Good morning, guys.

Irwin D. Simon -- Interim Chief Executive Officer

Good morning, Owen.

Owen Bennett -- Jefferies -- Analyst

And -- yeah, just a couple of questions from me. First of all, on the guidance capacity and looks like -- coming online as expected and with Health Canada expediting Diamond now. I was just wondering, and what sort of industry growth do you need to see, or are you planning on those assumptions to hit that CAD650 million, CAD700 million? And then maybe if you could give a bit of color in terms of how you see the mix between flower and new derivative products in that CAD650 million to CAD700 million. And then my follow-up is just any more color around the US you briefly mentioned partnerships and alliances for growth, kind of, is -- we expected to hear something around the US any time soon? Thank you.

Carl Merton -- Chief Financial Officer

Okay. That's all I like the, the multi-part question. So we'll -- let's deal with it in steps. In terms of the split between dried flower and the new derivative products, we've been on record multiple times. We think that dried flower remains a predominant share of the market, going forward. But -- but the vapes category and the new derivative products start to take significant amount of market share fairly quickly. Our internal models are really based around 60% market share for dried cannabis, 20% to 30% for vapes, and the remainder being split between drinks, edibles, and the other new product formats.

In terms of growth within the industry itself and our ability to meet our guidance and we see a couple of different things; one, we see our ability over the last few quarters to steal significant amounts of share in this space driven by the strength of our brands. We are consistently hearing from the individual store owners more and more people come in and asking for our individual brands. And the sales capabilities we have today are really -- were really driven by the amount of supply we have and the supply frees up. We see being able to steal more space on the shelf and be able to steal more share. We do have some growth forecasted in our number for new store openings. We recently saw that Quebec has made an announcement. We see Ontario has got some new stores coming on. Obviously, the -- those new stores and their ultimate opening will impact that. But as of today the information we have, we believe those will help drive that number as well.

Irwin D. Simon -- Interim Chief Executive Officer

And just on that, our brands have only been around less than a year, and the awareness team is built, and this is an industry that's tough to build brands, because you're not allowed to advertise the brands, so it's getting the consumers to try and repeat sales. So I come back and say, just think of our brands are around for five years consumers then start to know our brands, know the quality of our brands, and why it's much better to be buying our brands at retail outlets then be buying products in the illicit market and that's the biggest opportunity. 25% of sales only comes today from recreational products that are sold in stores. The big opportunity for us is how we continuously take away sales from the illicit market.

So -- and as Carl said, Canada expects to have over 3,000 stores within the next three years to five years with a 1,000 year in Ontario. So just by additional store expansion, additional products and us with our brands out there creating brand awareness and educating the consumer, the value of buying the brand in the stores, so the illicit market will drive our sales. Also there is a big focus here on medical with the niche joining us and taking over our medical business. We think there is a lot of patients that we can add to our medical database there. So the opportunity there are tremendous.

In regards to our US growth, spending 25 years, building a consumer products company in the US, we are talking to multiple partners in regards to strategic opportunities and is that strategic opportunities now with products that we would look at today that have the potential to be converted to CBD or THC or medical when ultimately becomes legal. I -- what I've seen is this year there is a lot of partners that want to jump into it. And what I want to make sure is, the partners who want to join Aphria, or partner up with Aphria, because they come back and they look at our facilities and maybe when they look at what we're doing in regards to the vapes. They look at what we're doing in regards to drinks and edibles and all of that research has been done. So that's the kind of partners they want to do.

So there's going to be a lot of opportunities for us. I think, the wrong strategy was jumping in too soon because when he jumped in too soon, you don't know when legalization is going to happen? You don't know, if it's just going to be medical, you don't know if it's rec. And they're still out there with the FDA and the USDA trying to figure out in regards to CBD. So I want to make sure, when we do it, we got a plan, we know what products, we know what's legal, and we know, if it's all the US certain states, or it's just medical. So, absolutely the opportunities there and we're working on it.

Owen Bennett -- Jefferies -- Analyst

Okay. Thanks guys. Very helpful. Appreciate it.

Irwin D. Simon -- Interim Chief Executive Officer

Thank you.

Operator

Your next question comes from Brett Hundley with Seaport Global. Your line is open.

Brett Hundley -- Seaport Global -- Analyst

Hey, good morning, guys and congratulations on this quarter. Carl, thank you for giving the expectations on working capital and capex for Q2. If I can press you a little bit, can you give us a sense of how your cash burn might trend beyond that? So I guess at a high level, we would expect cash burn to drop down in Q2 relative to Q1. At a high level, would you expect it to flat line for a couple of quarters there, or should we see continued drops thereafter?

Carl Merton -- Chief Financial Officer

For the next few quarters, I think, the flat line plays out more. We still having investments to make in Germany and Colombia that are announced. And then once we go through those pieces that you'll start to see the capex component of that number come down. We don't anticipate any major changes on the financing side, in terms of debt repayments. And we -- we will have a little bit of a working capital increase as Diamond comes online, but the majority of the working capital increase for Aphria One has already been incurred.

Brett Hundley -- Seaport Global -- Analyst

Thank you. That's helpful. And then following onto Owen's question about guidance. I want to dig in on the other part of guidance, which is EBITDA, and really get a sense of how fit Aphria is going forward in coming quarters here? You know, I know you guys are optimistic some of us on the other end of the phone have become more pessimistic about the Canadian market up ahead. When you look at your EBITDA range of CAD88 million to CAD95 million for fiscal '20, can we talk to some of the stress tests that you might have put in place around this guidance? Some of the broad themes are underlying assumptions within this range? So there's some of us on the other end of the call can get comfortable of how you're modeling that range for fiscal '20 given all the moving parts that's around the industry right now? Thank you.

Carl Merton -- Chief Financial Officer

Yeah. So, I think the best way to answer that is a big chunk of those increases in EBITDA are being driven by the increased capacity coming online with Aphria Diamond and the cost expectations we have for growing product in that facility. If you look at all of our expansions and have visited our facility, you'll know that we -- the Aphria One facility is set up in five different parts. And as we move from part to part, we've refined and we've changed how we grow and we've changed how we set up. When we build Diamond, we took the best -- we took the best that we had and that's how we organize Diamond.

And so you've got big -- sorry, you've got smaller expectations on costs and bigger amounts of gross margin flowing through that facility as a result. We are sitting at a cash cost of CAD1.35 in the quarter, and -- sorry CAD1.43 in the quarter and we're expecting below CAD1 as we ramp into -- as we ramp into Diamond and get that fully operational. The scale that we get from our facilities drives out a number of costs at Aphria One. We're still in the process of ramping up that facility. It's capacity was at 55,000 -- sorry, it's ramp was at 55,000 at the end of the quarter.

We've built pieces into the model to -- through our EU-GMP and our expectations on our ability to transfer product from Canada and start moving that internationally. And so as some of the demands in Canada, as some people are expressing some expected slowdown, we have the capability of moving that product from Canada to international opportunities at higher prices. That's built into those moments.

Brett Hundley -- Seaport Global -- Analyst

Thank you.

Operator

Your next question comes from Graeme Kreindler with Eight Capital. Your line is open.

Graeme Kreindler -- Eight Capital -- Analyst

Yeah. Hi, good morning, and thank you for taking my questions. I don't mean to harp on the guidance point here, but just with respect to the stress test, one element, specifically from the retail side of things. I understand there's been a lot of success in stealing share at this point in time. I'm just wondering, what the thoughts are with respect to opportunities for sell-through given the Ontario retail situation's been pushed back a bit? I know there's been some commentary at Quebec to increase that, but just wondering how many bumps along the way with respect to some of these key markets that retail could affect that outlook as well? Thank you.

Irwin D. Simon -- Interim Chief Executive Officer

So, hi. Number one, I think is, goes back to what I originally said. The opportunities for us in the retail market with additional stores opening up is tremendous. And I think in the Ontario market it goes 25 stores. The majority of the year was a lot and sold online. I think there is lots of change coming to the Ontario market. Is it going to be shipped direct to the stores, etc. But the key -- the key to all this is having good products with good brands and good pricing. And that's why we've built out under Bernie, the infrastructure and the sales team to get out there and make sure we got the right displays, where were placed in the stores. We got the right products. And working with the individual stores and the retailers to ensure that they know the Aphria brands; whether it's Solei, whether it's RIFF, whether it's Broken Coast.

And I think at the end of the day, I mean, this industry is just a year old. And the important part for us is, that we have supply and that's been the biggest challenge we've had all year with supply and with Aphria Diamond ultimately coming on and having over 600,000 plants. We will be able to have supply. Last but not least is being that producer of quality products is going to be important to us and also that producer of quality products at a lower cost. And ultimately Aphria with its brands, its products, its ability to ship, its infrastructure with sales organization, its infrastructure with its marketing group and building brand awareness. We feel good about achieving those numbers and winning over the consumer.

Graeme Kreindler -- Eight Capital -- Analyst

Okay. Appreciate the color there. And just for my follow-up here. With respect to the ramp of that on the guidance for the fiscal year, with the average revenue growth, if I ask correct, looking like it needs to be something around 60% a quarter. Is it fair to say that a much more of that growth is expected toward the latter half of the year considering where that's going to fall in terms of the roll-out with [Indecipherable]?

Irwin D. Simon -- Interim Chief Executive Officer

Yes. And that is all with Diamond coming on board rolling note on edibles and vapes etc., and continuously expanding the distribution and more and more stores opening up.

Graeme Kreindler -- Eight Capital -- Analyst

Okay, thank you.

Irwin D. Simon -- Interim Chief Executive Officer

Thank you.

Operator

Your next question comes from John Zamparo with CIBC. Your line is open.

John Zamparo -- CIBC -- Analyst

Thanks, good morning. I wanted to stick with the guidance as well. I appreciate the color you gave Carl on future expectations of market composition, but can you say what percent of that CAD88 million to CAD95 million comes from derivative products specifically?

Carl Merton -- Chief Financial Officer

We haven't publicly released that.

John Zamparo -- CIBC -- Analyst

Okay. And I think --

Carl Merton -- Chief Financial Officer

I think it's important that we're committing to our recreational products and growing our distribution and growing our brands and our products, but not to break it down and we haven't broken it down by product line or category.

John Zamparo -- CIBC -- Analyst

Okay, understood. Thanks. So my follow-up is on the Aleafia contract, I know you said in your press release this is a material just to clarify though is none of the original EBITDA guidance including contributions from that contract, or is it that you assume you'll find new buyers and assuming it's the latter, what is that you assume on wholesale versus retail for that product?

Carl Merton -- Chief Financial Officer

So, number one, the Aleafia contract was a legacy agreement. It was built into our absolutely guidance. And we expect to replace that with retail customers and other products to do support those sales that we wouldn't have got from Aleafia and at better prices and better opportunities out there within both flower and oil prices.

John Zamparo -- CIBC -- Analyst

Okay, thank you.

Carl Merton -- Chief Financial Officer

You're welcome.

Operator

Your next question comes from Matt Bottomley with Canaccord Genuity. Your line is open.

Matt Bottomley -- Canaccord Genuity -- Analyst

Good morning. Thanks for taking the questions. I just want to circle back on sort of the vaping headlines we're seeing in the US. I think a lot of us have at least a high level understanding as to what some of those issues are, and I know, when you spoke to them, but I imagine this is a bit of a PR issue for Health Canada and the federal government to have to navigate in this launch. So is there any color coming from them with respect to what they might be communicating to the public? And if they might slow down the potential flow through to the retail stores of these products, or they completely agnostic to the whole issue as it stands right now?

Irwin D. Simon -- Interim Chief Executive Officer

So we have not heard anything from Health Canada. And I think Health Canada has said, they will continue to evaluate. But again, what I said is this year, I think, what we want to ensure is the safety and quality of our products. And I think all indications so far, this is coming from vapes that are purchased through the illicit market, it's coming from products that are adulterated, it's coming from hardware that's never gone through quality testing. This comes back and just shows why it's so important for regulation. This is important, why it's so important to have brands and quality products because the consumer knows that they're getting a product that is safe that the hardware has been tested and the product they're getting has been tested. So we don't like to see sickness. We don't like to see illness. And we don't like to see anything that happening from vaping, but I think this comes back and just shows why consumers need to be buying the products and approved retail outlets and buying it from approved suppliers that have gone through the quality here.

Matt Bottomley -- Canaccord Genuity -- Analyst

Okay, thanks. And just a follow-up maybe for Carl. Just going back to the fiscal 2020 outlook again, I know there is a lot of commentary given this quarter and prior quarters on where you are in your overall build out, in order to achieve those numbers. But overall, if you were to assume the Canadian retail roll out goes horribly, just for the sake of argument, how much leverage do you have to put that distribution into international channels to better hit those numbers? So I guess a simple way of saying it is, if the Canadian market completely erupts on you, how sensitive is your CAD88 million to CAD95 million there?

Carl Merton -- Chief Financial Officer

We have the ability to, to move product through international markets through once we have the EU-GMP certification. We have -- we have significant demand through our operations in Italy, Germany, Colombia and Argentina. And those are just our customers. We're also received on a daily basis emails from people wanting to buy product from us internationally that aren't our actual own subsidiaries. We're very confident in our ability to deliver product from Canada to overseas market in a downside scenario.

Irwin D. Simon -- Interim Chief Executive Officer

But just on that, I think again, as we see the rest of the world and international being legalized in medical. The GMP certification opportunity for us is well within the hundreds and hundreds of millions of dollars and today we're selling minimal product there. So that is a big opportunity. But just to come back, I am confident with the Canadian market ultimately and I see the opportunity in this Canadian market only being legalized for just less than a year. And as I said before having these brands that are new to consumers and there is a major market today that can be taken away from the listed market of CAD4 billion. That is where the opportunity is, and that is where we have invested, and that's ultimately where Aphria will get to that CAD1 billion mark, we'll be able to generate tremendous amount of EBITDA and be able to generate a tremendous amount of cash.

Matt Bottomley -- Canaccord Genuity -- Analyst

Okay. Thanks guys.

Irwin D. Simon -- Interim Chief Executive Officer

Thank you.

Operator

Your next question comes from Justin Keywood with GMP Securities. Your line is open.

Justin Keywood -- GMP Securities -- Analyst

Good morning, and thanks for taking my call. Just on the 12% market share I mentioned, what was that up from the prior quarter? And how would that rank overall like -- like you said first, second or third?

Carl Merton -- Chief Financial Officer

So it's up four points from the prior quarter. And from a ranking standpoint, I'm not sure what you mean in a ranking standpoint?

Justin Keywood -- GMP Securities -- Analyst

Like -- as far as the total market share like would that be second, third, or would that be like first, as far as leading market share?

Carl Merton -- Chief Financial Officer

You mean as a company, as a brand, as a product I'm not sure what you're asking me?

Justin Keywood -- GMP Securities -- Analyst

So if it's 12% of the market like who would hold the first market share, like would that comprise of 15%?

Irwin D. Simon -- Interim Chief Executive Officer

So as you heard we only have access to Ontario data, we don't have national data.

Justin Keywood -- GMP Securities -- Analyst

Okay.

Irwin D. Simon -- Interim Chief Executive Officer

But Ontario being the biggest market is a good indication for the rest of Canada.

Justin Keywood -- GMP Securities -- Analyst

All right. Maybe just another question, what percentage of market share do you assume in your guidance?

Carl Merton -- Chief Financial Officer

It's still growing from the 12% in Ontario.

Irwin D. Simon -- Interim Chief Executive Officer

Right. So right now, we only have data on the Ontario market. And again as I said before, with that is number of stores that are opened today with the number of stores that will open, we should only increase market share, over the next three quarters for us or two-and-a-half quarters.

Justin Keywood -- GMP Securities -- Analyst

Okay. And in your guidance, do you have a target number of stores that you anticipate to be opened by them?

Carl Merton -- Chief Financial Officer

We do have a certain amount of stores, do we have it down to a signs by timing and date and stuff like that, no. I think there's couple of ways we're looking at it. We're looking at our supply and supplying our current stores, new store openings and new product lines that will roll out during the year.

Justin Keywood -- GMP Securities -- Analyst

Okay. Thank you for taking my questions.

Irwin D. Simon -- Interim Chief Executive Officer

Thank you very much.

Operator

There are no further questions queued up at this time. I'll turn the call back over to management.

Irwin D. Simon -- Interim Chief Executive Officer

Thank you very much everybody for listening to our call today. As you heard, our last two quarters, there's a lot of things happening at Aphria, and with that we will continue to do that. I'm excited, in regards to our execution. I really got to come back and say, thank you to our team members of 1,200 around the world that have been working endlessly to get us to where we are. I want to thank our Board of Directors for their support. As I said some of them will be leaving us at our -- this AGM and not to be running. Thank you very much to them.

Listen, this is a new industry. It's -- like I said, one-year old Thursday. And there has been a lot of start -- stops and starts and a lot of starts and stops. And with that there is a lot of opportunity here. I came back as I've spend a lot of time on this in coming out of the consumer packaged goods industry for 25 years. I do see a lot of similarities. But I come back and see there is a market out there CAD5 billion that is sold in both the illicit and the recreational. And our big focus and strategy has to be how we gain consumers' confidence and how we gain consumers' awareness of our brands that they're going to buy from retail stores and going to buy our brands and products and not be buying from the illicit market.

Secondly is this year, as we expand our product portfolio come out with new products and quality products and products that are well priced is something that we will continue to do and the marketing teams and the sales teams today are working together. One of the big things in my old world, we had Nielsen numbers, we had IRI numbers, and we don't have that data at our fingertips today. And with that is data and content and we are building around analytics, we are building around AI and building our products and important is the processes that we have in place. A year from today this will be a totally different industry than it is today. And that is the packaging that we are bringing into play in regards to sustainability, the products that we'll bring into play. But what I can reassure you is our focus is on quality, our focus is on safety, our focus is putting the great products out there. Our focus is on educating the consumer and ensuring these products are in the hands from a recreational standpoint to the right consumer. Our focus is to make sure we're putting out vapes or drinks. There are quality products.

So with that, I'm excited about where Aphria is going. I'm excited, ultimately to get our license that Aphria Diamond that would give us adequate supply of 255,000 kilos. I'm excited about the opportunities with our medical business, and that's an area that we had not focused on over the past year, and it was more on the rec side. But now that will be a big focus for us. And I really see the opportunity on a global basis, as we bring our medical businesses together and we see the opportunities learning from patients all over the world. As I said I was down in Buenos Aires few weeks ago, and was working with one of the hospitals where we have been. And what we're seeing is young patients having 300 plus seizures a day in epilepsy and administering CBD to them seeing their seizures go down to zero. So there's a lot happening both from the medical, from the rec, from the new product, from the gross standpoint, the processing.

The other big thing is, those have been to Leamington, at certain times, what's happening there from an automation standpoint and just in our pre-rolls, where we're doing it for a minute. We now have automation in that facility, where we're doing 5,000 an hour. So we'll continuously evolve on our processes, our automation. As we're going through scripts and presentations last night, we were talking about packaging. Last year this time we are paying CAD3, CAD5 for certain amount of packaging that came out last year when products came out. We continuously come back today and are looking at new sustainable packaging that are -- we're purchasing it for less than CAD1 today. So a lot has happened in the year. There is a lot of movement and tremendous amount of change in Aphria. And my objective is with this team that Aphria becomes the number one leading global cannabis company around the world.

Thank you very much for your time and I hope everyone had a great Thanksgiving and we'll speak to you again soon.

Operator

[Operator Closing Remarks]

Duration: 55 minutes

Call participants:

Katie M. Turner -- Investor Relations

Irwin D. Simon -- Interim Chief Executive Officer

Carl Merton -- Chief Financial Officer

Owen Bennett -- Jefferies -- Analyst

Brett Hundley -- Seaport Global -- Analyst

Graeme Kreindler -- Eight Capital -- Analyst

John Zamparo -- CIBC -- Analyst

Matt Bottomley -- Canaccord Genuity -- Analyst

Justin Keywood -- GMP Securities -- Analyst

More APHA analysis

All earnings call transcripts

AlphaStreet Logo